Penicillamine
Wilson Disease
Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Orphalan
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07465718CT.gov Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. | — | Not Yet Recruiting | — | — | — |
NCT03957720CT.gov The Individual Therapy for Patients With Wilson's Disease | — | Unknown | — | — | — |
NCT03539952CT.gov Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Wilson Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Penicillamine (this asset) | Orphalan | P3 | BB · 69 |
| Zinc Acetate | Nobelpharma | P4 | BBB |
| Teta 4Hcl | Orphalan | P3 | BBB |
| Zinc D-Gluconate (1:2) | Jun Li | P4 | BBB |
| Trientine | Excelsior | P3 | BB |
| Alxn1840 | Alexion Pharmaceuticals, Inc. | P3 | BB |
| Gandouling | Jun Li | P4 | BB |
| Tetrathiomolybdate | National Center for Research Resources (NCRR) | P3 | B |
| Bis-Choline Tetrathiomolybdate | Alexion Pharmaceuticals, Inc. | P2 | B |
+11 more in the Wilson Disease cohort
Other indications for Penicillamine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Central Nervous System Neoplasm | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Penicillamine in Wilson Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/penicillamine-wilson-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →